On June 20, 2023, the U.S. Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR)
On June 20, 2023, the U.S. Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR)
More